Depression with cognitive impairment, so called depressive pseudodementia, is commonly mistaken for a neurodegenerative dementia. Using positron emission tomography (PET) derived measures of regional cerebral blood flow (rCBF) a cohort of 33 patients with major depression was studied. Ten patients displayed significant and reversible cognitive impairment. The patterns of rCBF of these patients were compared with a cohort of equally depressed non-cognitively impaired depressed patients. In the depressed cognitively impaired patients a profile of rCBF abnormalities was identified consisting of decreases in the left anterior medial prefrontal cortex and increases in the cerebellar vermis. These changes were additional to those seen in depression alone and are distinct from those described in neurodegenerative dementia. The cognitive impairment seen in a proportion of depressed patients would seem to be associated with dysfimction of neural systems distinct from those implicated in depression alone or the neurodegenerative dementias.
Abstract
Depression with cognitive impairment, so called depressive pseudodementia, is commonly mistaken for a neurodegenerative dementia. Using positron emission tomography (PET) derived measures of regional cerebral blood flow (rCBF) a cohort of 33 patients with major depression was studied. Ten patients displayed significant and reversible cognitive impairment. The patterns of rCBF of these patients were compared with a cohort of equally depressed non-cognitively impaired depressed patients. In the depressed cognitively impaired patients a profile of rCBF abnormalities was identified consisting of decreases in the left anterior medial prefrontal cortex and increases in the cerebellar vermis. These changes were additional to those seen in depression alone and are distinct from those described in neurodegenerative dementia. The cognitive impairment seen in a proportion of depressed patients would seem to be associated with dysfimction of neural systems distinct from those implicated in depression alone or the neurodegenerative dementias. Primary depression with significant cognitive impairment, commonly referred to as depressive pseudodementia or the dementia of depression, may be mistaken for a progressive neurodegenerative dementia. 1 Depression itself may also be a concomitant of a progressive degenerative dementia, particularly in its early phases.2 The conjunction of depression and cognitive impairment frequently poses a clinical diagnostic problem which may hamper patient management. Recognition of a primary depression masquerading as a neurodegenerative dementia is clinically important because of its treatability. Depression with cognitive impairment can lead to misdiagnosis of primary degenerative dementia even in specialist centres.3 Misdiagnosis, more common in the elderly, may also occur in the presenium. 4 The extent of misdiagnosis may be inferred from a study which reported that 8% of patients with an index diagnosis of dementia were rediagnosed as depression on subsequent admission.6 Depressed patients with cognitive impairment demonstrate a significant improvement on quantitative assessments of cognition following treatment or on follow-up. 78 The neurobiological basis of depression related cognitive impairment remains obscure. Distinct patterns of focal cerebral metabolic abnormalities have been described in primary depression.9"0 The most consistent change described is a decrease in rCBF or metabolism in the left dorsolateral prefrontal cortex (DLPFC). We report a study of depressed patients, using PET derived measures of rCBF, which reveals a profile of abnormality, distinct from that seen in depression alone, in depression related cognitive impairment.
Subjects and methods
Patients included in the study were recruited from district psychiatric services in north London and the National Hospital for Neurology and Neurosurgery. Potential participants indicating willingness to cooperate with the study and ability to give informed consent were administered The Schedule for Affective Disorders and Schizophrenia (SADS).
" Patients who met Research Diagnostic Criteria (RDC)12 for major depressive disorder were considered further. Exclusion criteria were a past or present history of neurological disease, drug or alcohol abuse (based on the SADS) or any significant past medical illness. Subjects were also excluded if they scored over 16 Subsequent follow up of these patients revealed a clinical course con-sistent with a primary depression and with significant improvements of their scores on both the MMSE and CAMCOG.
All subjects had steady state measurement of cerebral blood flow using 15Q as previously described.'7 Studies were performed using a PET scanner (CTI Knoxville model 931-08/12 CTI PET Systems, Tennessee, USA). The physical performance of this scanner has been described elsewhere.'8 Measured attenuation corrections were made with the ratio of counts in blank and transmission scans obtained using a 68Germanium ring source. Emission scans were reconstructed using a Hanning filter with a cut off frequency of 0 5 cycles per pixel. The images were zoomed by a factor of 2-29, resulting in an effective pixel size of 2-05 mm and a resolution of 8x5 mm. All studies were performed in the supine position in a room with dimmed lights and minimal environmental noise extra to that of the scanner's cooling system. For each subject a polystyrene head mould was made which was used to ensure correct positioning in the scanner and relative head immobility. A 22 g teflon cannula was inserted into a radial artery after Allen's test for collateral circulation and infiltration of the skin with 1% Marcain (Bupivicaine). The subjects were aligned in the scanner with reference to a laser beam system so that the detectors were parallel to the orbitomeatal (OM) line. '5Oxy-gen was administered by inhalation via a light plastic face mask surrounded by a clear perspex extractor hood. For the estimation of CBF and CMRO2 subjects inhaled C'502 (0-75 MBQ/ml, flow rate 500 ml/min for 18 minutes) and 'O2 (2-0 MBQ/ml, flow rate 500 ml/min for 18 minutes) respectively. Three arterial blood samples were taken during each emission scan. These samples were centrifuged and plasma and whole blood activity measured in a well counter, cross calibrated with the PET scanner. Two arterial samples were taken for estimation of Haemoglobin, pACO2 and pAO2. Blood gas estimation was undertaken in all subjects but revealed no difference between patient groups in pACO .
Image analysis was performed on a SUN 3/60 Workstation (Sun Microsystems Europe, Surrey, UK) using an interactive image analysis software package (ANALYZE, Biodynamic Research Unit, Mayo Clinic, Rochester, MN, USA). The functional images were checked for artifacts and corrected for yaw and roll. The 15 original planes of data (6-75 mm interplane distance) were bilinearly interpolated to 26 terms of medication status with more of the impaired group taking psychotropics. The medication details of both groups are presented in table 3. To examine the possible effects of medication on rCBF we examined the total cohort of patients and compared medicated (n = 19) with unmedicated (n = 14) patients in terms of rCBF. This comparison failed to identify any foci of significant change even at a lower threshold of significance than that utilised in the comparison of cognitively impaired with non-impaired patients. Table 2 Coordinates of the pixels where the most significant differences in blood/low were identified. The reference stereotaxic atlas is that of Talairach and Tournoux. ' The CBF values are in units of mlldl tissuelmin, and have been adjusted for a global mean blood flow of 50mlidlimin. procity between the medial prefrontal cortex and the cerebellar vermis, mediated via prefrontal-cerebellar connections, in relation to cognitive function might therefore explain our findings.40 41 The profile of rCBF described in this study is distinct from that seen in the more common forms of neurodegenerative dementia. In Alzheimer's type dementia the typical pattern of rCBF and metabolic abnormalities are posterior in location, symmetrical in distribution, with an emphasis on the inferior parietal and posterior superior temporal cortical areas. 42 The cognitive impairments seen in dementia of the Alzheimers type and those seen in primary depressive illness may be due to dysfunction in separate neuroanatomical systems. In the less common frontal type neurodegenerative dementias decreases in rCBF have been described, but these are bilateral and more extensive than the pattern described in this study. We would, however, caution against an inter-.pretation of our findings that might suggest a possible clinical role in differential diagnosis. We have no information on the specificity or sensitivity of the findings. The mean age of our sample is of course considerably younger than that of typical patients with neurodegenerative types of dementia. It is also important to bear in mind that the changes we describe are additional to those that underlie depression itself. The patients described in our present study have been reinvestigated at a minimum of one year following index assessment with most showing recovery from depression and none showing a deterioration in cognitive function. This suggests that a simple longitudinal clinical assessment of patients with depression and cognitive impairment is sufficient in most cases to clarify diagnosis. The findings of our investigation can, however, be interpreted as implicating a focal disturbance in the left medial prefrontal cortex as critical in the cognitive impairment of depression.
